<DOC>
	<DOCNO>NCT01395420</DOCNO>
	<brief_summary>This open-label study divide 2 part 3 cohort determine concentration Avibactam Ceftazidime line lung blood .</brief_summary>
	<brief_title>Study Assess Concentration Avibactam Ceftazidime Epithelial Lining Fluid Plasma</brief_title>
	<detailed_description>A Phase I Open-Label , 2-Part , 3-Cohort , Single-Centre Study Assess Concentration Avibactam Ceftazidime Epithelial Lining Fluid Plasma Using Least Two Different Dosing Regimens Healthy Volunteers</detailed_description>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure Healthy male female subject vein suitable cannulation repeat venepuncture ; female subject must postmenopausal surgically sterile . Female subject must negative pregnancy test screen admission unit , must lactate must nonchildbearing potential Male subject willing use barrier contraception ie , condom , dose 3 month dose IP Have body mass index ( BMI ) 19 30 kg/m2 As judged Investigator , subject must able understand willing comply study procedure , restriction requirement History presence clinically significant disease disorder ( include history chronic respiratory disease eg , asthma , chronic obstructive pulmonary disease [ COPD ] , cystic fibrosis interstitial lung disease ) , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug Known allergy lidocaine/lignocaine , midazolam , alfentanyl topical anaesthetics/sedatives similar class agent Any clinically significant illness , medical/surgical procedure trauma within 4 week first administration IP Any clinically significant abnormality physical examination , lung function test , ECG , clinical chemistry , haematology , coagulation screen , urinalysis result judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>open label</keyword>
	<keyword>healthy male female ( post menopausal ) volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>CAZ104</keyword>
	<keyword>Avibactam</keyword>
	<keyword>Ceftazidime</keyword>
	<keyword>open label , least 2 different regimen , concentration investigational product ( IP ) , CAZ104 , Avibactam , Ceftazidime , Cmax , tmax</keyword>
</DOC>